Publicaciones en colaboración con investigadores/as de Eli Lilly and Company (6)

2021

  1. ERK inhibitor LY3214996-based treatment strategies for RAS-driven lung cancer

    Molecular Cancer Therapeutics, Vol. 20, Núm. 4, pp. 641-654

2020

  1. Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 117, Núm. 39, pp. 24415-24426

2019

  1. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

    The Lancet, Vol. 394, Núm. 10193, pp. 121-130

  2. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

    The Lancet, Vol. 394, Núm. 10193, pp. 131-138

2015

  1. Overexpression of penicillin V acylase from Streptomyces lavendulae and elucidation of its catalytic residues

    Applied and Environmental Microbiology, Vol. 81, Núm. 4, pp. 1225-1233

2012

  1. Guidelines for the use and interpretation of assays for monitoring autophagy

    Autophagy, Vol. 8, Núm. 4, pp. 445-544